Nature Communications / LinkedIn · Jul 2026
Ataraxis said Nature Communications published a positive clinical validation study of Ataraxis Breast; the company highlighted results across 8,161 patients and 15 cohorts.
Company research
Public company, workplace, funding, and market signals
Updated Jul 29, 2026
Overview
Ataraxis AI is a New York-based AI precision-medicine company spun out of NYU that builds multimodal oncology tools to predict cancer recurrence and treatment benefit. Its flagship product is Ataraxis Breast, a breast-cancer prognostic/predictive suite built on the Kestrel/Falcon pathology foundation-model stack. I did not surface a public GitHub or X account in the sources reviewed.
Primary product
Ataraxis Breast (including RISK, CTX, and NEO modules)
Founded
2023
Headquarters
New York, New York, United States
Team size
30-40
Work style
Flexible
Industry
Artificial Intelligence
Sub-industry
Precision medicine / oncology diagnostics
Open Positions
10 jobs at Ataraxis
Scientific Strategy, Oncology
On-siteMedicalNew York HQ4d ago
On-site